Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bryant ranch prepack - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol capsules administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyro

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bryant ranch prepack - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol capsules administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. calcitriol should not be given to patients with hypercalcemia or evidence of vitamin d toxicity. use of calcitriol in patients with known hypersensitivity to calcitriol (or drugs of the same class) or any of the inactive ingredients is contraindicated.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol rm is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol rm is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol rm is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol sg is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol sg is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol sg is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol kp is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol kp is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol kp is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol cw is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol cw is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol cw is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: glycerol; sorbitol solution (70 per cent) (non-crystallising); butylated hydroxyanisole; iron oxide yellow; fractionated coconut oil; butylated hydroxytoluene; gelatin; iron oxide red; purified water - calcitriol-ga is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. calcitriol-ga is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. calcitriol-ga is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: butylated hydroxyanisole; iron oxide red; purified water; gelatin; iron oxide yellow; fractionated coconut oil; glycerol; sorbitol solution (70 per cent) (non-crystallising); butylated hydroxytoluene - calciprox is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. calciprox is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. calciprox is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

aristo pharma gmbh - betamethasone; calcipotriol - gel - 50 microgram/g +0.5 milligram(s)/gram - calcipotriol, combinations

Australia - engleză - Department of Health (Therapeutic Goods Administration)

leo pharma pty ltd - calcipotriol, quantity: 50 microgram/g - ointment - excipient ingredients: disodium edetate; dibasic sodium phosphate dihydrate; dl-alpha-tocopherol; liquid paraffin; steareth-2; propylene glycol; purified water; white soft paraffin - calcipotriol ointment is indicated for the topical treatment of chronic stable plaque type psoriasis vulgaris in adult patients. indications as at 26 march 2002: daivonex ointment is indicated for the topical treatment of chronic stable plaque type psoriasis vulgaris in adults and children (see use in children). in adult patients, daivonex ointment may also be used in combination with either phototherapy, or systemic acitretin or cyclosporin.